Estradiol Tablets

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D2-23-D-0001

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

Brookhaven, New York, UNITED STATES

SourceSAM
Documents3
The Defense Logistics Agency (DLA) Troop Support has issued an award notice for a national contract, identified as SPE2D2-23-D-0001, pertaining to the supply of Estradiol Tablets. This procurement falls under the North American Industry Classification System (NAICS) code 325412, which covers Pharmaceutical Preparation Manufacturing, and is further classified by Product Service Code 6505, indicating drugs and biologicals. The primary objective of this contract is to ensure the reliable provision of Estradiol Tablets, a critical pharmaceutical product, to support the needs of federal entities. The scope of the contract encompasses the manufacturing and delivery of these tablets to the designated place of performance in Brookhaven, New York. The intended outcome is to maintain a consistent and high-quality supply of Estradiol Tablets, thereby supporting the health and medical readiness of personnel served by DLA Troop Support. Key requirements for contractors include demonstrated capabilities in pharmaceutical manufacturing, specifically in the production of Estradiol Tablets, adherence to stringent quality standards, and compliance with all applicable federal regulations governing drug manufacturing and distribution. Contractors are expected to deliver products that meet the specifications outlined by DLA Troop Support, ensuring safety, efficacy, and reliability throughout the contract lifecycle. The contracting entity for this procurement is DLA Troop Support, a federal office responsible for providing logistical support to the Department of Defense and other federal agencies. The contract is managed from their office, with primary and secondary points of contact available for inquiries: Ryan Ferry ([email protected], 215-737-3182) and Jason Wray ([email protected], 215-737-0614). This award notice is currently active and was posted on November 9, 2023. Interested parties can access further details and attachments via the official SAM.gov opportunity listing (Opportunity ID: 4ba713cec4eb4ccc89a1e1cb98a62aa7) at https://sam.gov/opp/4ba713cec4eb4ccc89a1e1cb98a62aa7/view. Contractors evaluating this opportunity should note that it is a federal procurement for pharmaceutical manufacturing, with performance required in Brookhaven, New York. The contract is not identified as a set-aside for small businesses or other socioeconomic categories, and no special considerations beyond standard federal requirements are indicated in the notice. The essential elements of this contract—manufacturing, quality assurance, and reliable delivery of Estradiol Tablets—will remain constant throughout its duration.